Jones Financial Companies
HRTX icon

Jones Financial Companies’s Heron Therapeutics HRTX Stock Holding History

Jones Financial Companies’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.5K Buy
30,062
+2,107
+8% +$2.44K ﹤0.01% 3234
2025
Q4 		$36.3K Buy
27,955
+3,867
+16% +$4.78K ﹤0.01% 2673
2025
Q3 		$29.1K Buy
24,088
+23,661
+5,541% +$37.5K ﹤0.01% 2605
2025
Q2 		$914 Buy
+427
New +$872 ﹤0.01% 3676
2025
Q1 		– Sell
-476
Closed -$728 – 3780
2024
Q4 		$728 Buy
+476
New +$772 ﹤0.01% 3189

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Jones Financial Companies's HRTX Position: Q1 2026 in Review

Jones Financial Companies increased its Heron Therapeutics (HRTX) stake by 7.5% in Q1 2026, buying an estimated $2.44K and bringing the position to 30,062 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3234.

Jones Financial Companies first reported a position in HRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $36.3K in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Jones Financial Companies held 30,062 shares of Heron Therapeutics worth $23.5K as of Q1 2026.
  • Jones Financial Companies bought 2,107 Heron Therapeutics shares in Q1 2026, an estimated $2.44K.
  • Heron Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3234 holding.
  • Jones Financial Companies first reported a position in Heron Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Jones Financial Companies's Heron Therapeutics position peaked at $36.3K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.